Mesa Laboratories (NASDAQ:MLAB) CFO Sells $123,853.21 in Stock

Mesa Laboratories, Inc. (NASDAQ:MLAB) CFO John Sakys sold 1,223 shares of the business’s stock in a transaction on Tuesday, June 16th. The stock was sold at an average price of $101.27, for a total value of $123,853.21. Following the completion of the transaction, the chief financial officer directly owned 16,538 shares in the company, valued at approximately $1,674,803.26. This represents a 6.89% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Mesa Laboratories Price Performance

Mesa Laboratories stock opened at $95.10 on Friday. Mesa Laboratories, Inc. has a 12 month low of $55.45 and a 12 month high of $113.99. The company has a current ratio of 1.72, a quick ratio of 1.29 and a debt-to-equity ratio of 0.78. The business’s 50 day simple moving average is $101.94 and its 200 day simple moving average is $90.77. The company has a market cap of $525.43 million, a price-to-earnings ratio of 79.25 and a beta of 0.94.

Mesa Laboratories (NASDAQ:MLAB) last released its quarterly earnings data on Wednesday, May 27th. The medical instruments supplier reported $1.53 EPS for the quarter, missing the consensus estimate of $1.78 by ($0.25). Mesa Laboratories had a return on equity of 20.96% and a net margin of 2.69%.The business had revenue of $63.72 million during the quarter, compared to the consensus estimate of $65.21 million. During the same period last year, the business posted ($1.31) earnings per share.

Mesa Laboratories Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, June 15th. Investors of record on Friday, May 29th were issued a dividend of $0.16 per share. The ex-dividend date of this dividend was Friday, May 29th. This represents a $0.64 annualized dividend and a dividend yield of 0.7%. Mesa Laboratories’s dividend payout ratio (DPR) is currently 53.33%.

Institutional Trading of Mesa Laboratories

A number of large investors have recently made changes to their positions in MLAB. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Mesa Laboratories by 4.9% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 3,068 shares of the medical instruments supplier’s stock worth $364,000 after acquiring an additional 143 shares during the last quarter. American Century Companies Inc. increased its stake in shares of Mesa Laboratories by 1.5% in the second quarter. American Century Companies Inc. now owns 13,431 shares of the medical instruments supplier’s stock worth $1,265,000 after acquiring an additional 194 shares during the period. BNP Paribas Financial Markets grew its position in Mesa Laboratories by 30.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 1,029 shares of the medical instruments supplier’s stock worth $69,000 after purchasing an additional 243 shares during the period. Deutsche Bank AG grew its holdings in Mesa Laboratories by 5.9% during the fourth quarter. Deutsche Bank AG now owns 4,440 shares of the medical instruments supplier’s stock worth $349,000 after acquiring an additional 248 shares during the period. Finally, Northwestern Mutual Wealth Management Co. increased its holdings in shares of Mesa Laboratories by 5,366.7% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 328 shares of the medical instruments supplier’s stock valued at $26,000 after purchasing an additional 322 shares in the last quarter. 90.60% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Separately, Weiss Ratings cut Mesa Laboratories from a “sell (d+)” rating to a “sell (d)” rating in a research note on Wednesday, June 3rd. Two research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Reduce” and a consensus target price of $94.00.

About Mesa Laboratories

Mesa Laboratories, Inc (NASDAQ: MLAB) is a global provider of instrumentation products designed for critical process monitoring, testing and calibration. Headquartered in Lakewood, Colorado, the company serves a diverse set of end markets including healthcare, pharmaceutical, food and beverage, energy and industrial sectors. With a focus on precision measurement and validation, Mesa Laboratories helps customers ensure regulatory compliance, product safety and operational efficiency across complex manufacturing and sterilization processes.

The company’s product portfolio encompasses biological and chemical indicators for sterilization process validation, digital data loggers and sensors for environmental monitoring, and optical gas analyzers with sample-conditioning solutions for oil, gas and petrochemical applications.